That is what the FDA wants too.
If it works then that's terrific, put it as SOC. Until then, the question is open. It might be a useful therapy for 30% or more of patients who genuinely get benefit or it might be expensive Disallowed. We need to know for sure.
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-94
-
- There are more pages in this discussion • 330 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.324B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $5.890M | 5.014M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4990 | $1.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 10536 | 2 |
View Market Depth
| Last trade - 15.59pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |